Cervical Cancer
USC professor honored with distinguished lectureship
American Association for Cancer Research honored Lourdes A. Báezconde-Garbanati, PhD, with the AACR Distinguished Lectureship on the Science of Cancer Health Disparities.
HPV vaccination substantially reduces risk for invasive cervical cancer
Quadrivalent HPV vaccination substantially reduced the risk for invasive cervical cancer among Swedish girls and women aged 10 to 30 years, according to results of a study published in The New England Journal of Medicine.
American Cancer Society: Start cervical cancer screening at age 25 years, phase out Pap
An updated guideline issued by the American Cancer Society recommends cervical cancer screening with the HPV test every 5 years from age 25 years to 65 years.
Chemotherapy, surgery for gynecologic cancer not linked to higher COVID-19 mortality risk
Women who underwent chemotherapy or surgery for gynecologic cancer and also had COVID-19 infection did not appear at significantly increased risk for death due to the novel coronavirus, according to study findings published in Cancer.
ASTRO issues guideline on radiation therapy for cervical cancer
A new guideline issued by the American Society for Radiation Oncology addresses the use of radiation therapy for the treatment of nonmetastatic cervical cancer.
Minimally invasive surgery may increase risk for death in early-stage gynecologic cancers
Minimally invasive surgical procedures appeared associated with an elevated risk for recurrence or death vs. open surgery among women with early-stage gynecologic cancers, according to results of two studies published in JAMA Oncology.
FDA grants fast track status to several agents
Addition of GX-188E to pembrolizumab improves response rate in advanced cervical cancer
The combination of pembrolizumab and GX-188E, a DNA vaccine targeting HPV types 16 and 18, conferred high response rates compared with pembrolizumab alone among a cohort of women with advanced, inoperable or metastatic cervical cancer, according to results of an interim analysis presented at the virtual American Association for Cancer Research Annual Meeting.
FDA grants fast track status to balstilimab for advanced cervical cancer
The FDA granted fast track designation to balstilimab for treatment of women with advanced cervical cancer.
Researchers verify link between minimally invasive surgery, higher recurrence risk in early-stage cervical cancer
Women who underwent minimally invasive radical hysterectomy for early-stage cervical cancer demonstrated had higher risk for recurrence than women who had open surgery, according to results of a retrospective, multi-institutional review published in Journal of Clinical Oncology.